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ABSTRACT
Gene therapy, cell therapy, and tissue engineering have the potential to revolutionize the treat-
ment of disease and injury. Attaining marketing authorization for such advanced therapy medicinal
products (ATMPs) requires a rigorous scientific evaluation by the European Medicines Agency—
authorization is only granted if the product can fulfil stringent requirements for quality, safety, and
efficacy. However, many ATMPs are being provided to patients under alternative means, such as
“hospital exemption” schemes. Holoclar (ex vivo expanded autologous human corneal epithelial
cells containing stem cells), a novel treatment for eye burns, is one of the few ATMPs to have been
granted marketing authorization and is the first containing stem cells. This review highlights the
differences in standards between an authorized and unauthorized medicinal product, and specifi-
cally discusses how the manufacture of Holoclar had to be updated to achieve authorization. The
result is that patients will have access to a therapy that is manufactured to high commercial stand-
ards, and is supported by robust clinical safety and efficacy data. STEM CELLS TRANSLATIONAL
MEDICINE 2018;7:146–154
SIGNIFICANCE STATEMENT
In February 2015, Holoclar was the first stem cell-based medicine to receive authorization for
commercial use throughout the European Union. Injury to the eye can destroy limbal stem cells
(LSCs) leading to loss of vision as the cornea is invaded by conjunctival cells. Holoclar uses a
patient’s own LSCs from the unaffected eye to form a graft grown outside the body. Graft
transplantation into the injured eye restores the LSC population allowing a normal transparent
corneal surface to be regenerated. This is a significant development in the field of regenerative
medicine—no other stem cell therapy has demonstrated sufficient quality standards and clinical
successes to achieve authorization status.
INTRODUCTION
Increasing numbers of advanced-therapy medici-
nal products (ATMPs), comprising gene therapies,
cell therapies and tissue engineered products, are
being administered to patients throughout the
European Union (EU). Authorization to market
ATMPs in the EU is regulated by the “ATMP Regu-
lation” (Regulation (EC) 1394/2007) and requires
an application to be made through the European
Medicines Agency (EMA). However, as yet, very
few ATMPs have applied for, or achieved, this
authorization. This may be due, at least in part, to
the fact that the pathway to regulatory approval
takes a substantial amount of expertise, time and
investment to navigate. Chiesi Farmaceutici S.p.A.
made this investment together with Academia, to
bring the product, Holoclar, through the central
authorization process. In February 2015, Holoclar
became the first stem cell-based ATMP to be
approved by the European Commission. This
paper considers the improvements in product
quality that had to be made to achieve this goal,
and their relevance to patients.
Application for marketing authorization in the
EU requires submission of a comprehensive prod-
uct dossier to the EMA. This dossier is then sub-
jected to an extensive and thorough scientific
assessment by the EMA’s specialist experts in the
Committee for Advanced Therapies (CAT). The
assessment is to determine if the requirements
for quality, safety, and efficacy have been met, so
that patients and practitioners can have high con-
fidence in the product. Table 1 highlights the key
differences in quality requirements between a
product granted marketing authorization
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compared to one that may be used clinically under other legal pro-
visions. Although this article focusses on product quality, it should
also be noted that authorization of a medicinal product brings
other additional requirements that support the product’s wide-
spread clinical use, including provisions of instructions for use
(which may be supplemented with detailed training materials),
product information for patients, organized safety reporting of any
adverse events (pharmacovigilance), and any obligations for further
clinical studies to increase the safety and efficacy data sets.
Holoclar (manufactured by Holostem Terapie Avanzate S.R.L.
and originally developed by Professors Graziella Pellegrini and
Michele De Luca) is a cell-based tissue engineered therapy that
replaces epithelial cells in a damaged cornea. Renewal and repair
of this surface depends on limbal stem cells (LSCs) which reside in
the limbus—a narrow zone between the cornea and the bulbar
conjunctiva. Ocular burns (chemical or physical) may destroy the
limbus causing limbal stem cell deficiency (LSCD), a condition that
allows bulbar conjunctival cells to invade the corneal surface in an
attempt to reform an epithelium. This process of conjunctivaliza-
tion results in neovascularization, inflammation, stromal scarring,
and corneal opacity leading to loss of vision [1]. Holoclar uses the
patient’s own (autologous) LSCs as a treatment.
There are three types of clonogenic keratinocytes defined as
holoclones, meroclones, and paraclones [2, 3]. The regenerative
potential of Holoclar mainly relies upon the highly proliferative
and self-renewing properties of holoclones which, as stem cells,
have the greatest growth potential of all keratinocytes. Holoclones
generate transiently amplifying (TA) cells—meroclones—which
have much lower proliferative capacity but frequently divide. Par-
aclones are also TA cells generated from meroclones and have
even lower proliferative capacity [4–6]. The purpose of both these
TA cell types is to form a stratified squamous epithelium [7]. This
process is illustrated in Figure 1, where holoclones are identified
by high level of expression of the marker, p63 (see “Efficacy”
section).
The manufacturing process, shown in Figure 2, is designed to
maintain the content of holoclones in the final administered Holo-
clar product, and is subject to rigorous safety controls throughout
Table 1. Key differences in quality requirements for advanced therapy medicinal products between those with and without marketing
authorization in Europe
Aspects of manufacture
Product with central European
Union marketing authorization
(e.g., Holoclar) Other products
Regulatory oversight Extensively reviewed and approved by
European Medicines Agency
National and/or local approval
(in most of the cases)
Relationship between product
quality and clinical outcome
Consistent product quality correlating
with extensive clinical experience
Unlikely to have extensive clinical experience
or an established manufacturing process
assuring consistent product quality
Manufacturing quality Full GMP for commercial product GMP level sufficient for initial clinical use
Manufacturing processes Process must be validated for consistency Process validation is not required
Process materials and excipients Quality and safety must be assured Local control of selection of materials
Testing Rigorous testing for critical quality attributes
that are correlated with clinical outcome
Test procedures must be validated
Extent of testing is less regulated, and not likely
to be able to be correlated with significant
clinical experience
Test procedure validation is not required
Shelf-life Based on stability studies with multiple batches Unlikely to have the same level of assurance
Safety from infectious agents Microbial and viral safety are subject to
rigorous assessment
Microbial and viral safety are subject
to local assessment
End use Instructions for use including training to health
care professionals approved and validated to
maintain quality attributes for clinical efficacy
Instructions for use are locally controlled
Abbreviation: GMP, good manufacturing practice.
Figure 1. The role of clonogenic keratinocytes in generation and
renewal of the corneal epithelium. (A): The holoclone differentia-
tion process from highly proliferative self-renewing holoclones to
transiently amplifying cells (meroclones and paraclones). A confocal
microscopy image of holoclone stem cells is on the left showing
high expression of DNp63a, an isoform of the p63 transcription fac-
tor. Due to this characteristic, these cells are also referred to as
p63bright cells. (B): Stem cells from (A) in their ocular context. Holo-
clones, meroclones, and paraclones are found in the basal layer of
the limbus with holoclones having the least abundance (10%–15%).
The basal layer of the cornea is populated by meroclones and para-
clones at the periphery, and only paraclones in the central cornea.
All suprabasal layers of the limbus and corneal surface contain ter-
minally differentiated cells which have no capacity for self-renewal
or proliferation (shown in gray). The conjunctival surface is com-
posed of epithelial cells (yellow) and a low proportion of goblet cells
(magenta) that are interspersed throughout.
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the process. The starting material is a small biopsy taken from the
limbus of the patient’s less affected or unaffected eye. Cells iso-
lated from this sample are enzymatically dissociated and seeded
as a single primary culture onto a layer of irradiated mouse feeder
cells, with growth factors, that promote LSC growth. Following pri-
mary culture expansion in media containing antibiotics, all cells
are recovered and cryopreserved as an “intermediate cell bank”
(ICB). This holding step has several advantages: (a) it provides time
for sufficient testing of the sample; (b) it enables timing of the
manufacture of the drug product to be aligned with patient, sur-
geon, and hospital facility availability; and (c) it can allow (depend-
ent on the quantity available) a contingency sample of patient
cells to be saved to be used in a second manufacturing round in
case of incomplete result or failure with the first Holoclar graft.
After thawing an ICB, it is seeded onto a fibrin matrix (secondary
culture stage) which also contains the same type of mouse feeder
cells; however, the media is changed to one that is antibiotic-free
but still contains growth factors. The fibrin matrix provides a solid
support on which the cells can be administered into the eye. After
culture expansion, support discs made of fibrin carrying the auto-
logous cells are prepared and packaged. Holoclar is then shipped
and administered to the patient by grafting into the injured eye
thus restoring the LSC reservoir [8].
A number of stem cell-based therapies have been used across
Europe with the same aim as Holoclar, and some are manufac-
tured using similar techniques (for reviews see [9, 10]). However,
none of them have been demonstrated to have the quality con-
trols required for a centralized marketing authorization. Principally
from a quality perspective, this paper examines the advantages
that Holoclar has to offer, having undergone the rigors of the
authorization process. We explain how, since its inception, the
manufacture of Holoclar has been substantially upgraded to meet
the requirements of a marketed product, and the benefits that
this brings to patients.
EFFICACY
Throughout extensive clinical experience, it was found that the
clinical success of Holoclar treatment had a positive correlation
with the percentage of holoclones present in the limbal culture [8,
11]. Holoclones can be reliably identified because they have a spe-
cific dimensional range and express high levels of DNp63a, the
main isoform of the transcription factor p63 [12, 13] expressed in
limbal cells, sustaining the regenerative potential of these cells
[13–16]. The percentage of p63bright cells was calculated in 91 pri-
mary cultures used to seed graftable secondary cultures, and sta-
tistical analysis showed that this parameter, was significantly
associated with clinical success (p5 .0114). The percentage of
cells that are p63bright at this stage was therefore designated as a
critical specification as a marker of product potency.
Using immunohistochemical analysis, the Company screens all
limbal cultures for the abundance of p63a, and those cells with a
strong signal (termed p63bright cells) within a pre-defined dimen-
sional range are identified as holoclones. This assay has been fully
validated, and used to ensure that all cultures of Holoclar contain
a sufficient proportion of p63bright cells prior to preparation for
administration. This specification is based on the average result
for batches yielding successful outcomes in the pivotal clinical effi-
cacy study plus/minus two SD. Batch cultures which met this spec-
ification were associated with successful outcomes, whereas
preparations with lower p63bright cell content were less likely to
be clinically effective [8, 11]. The test therefore saves patients
from undergoing an invasive procedure only to be given a graft
with insufficient holoclones, and therefore increases the prospects
of beneficial effect. The assay has also allowed optimization of the
ex vivo culture conditions to maintain in culture the p63bright cells
so that the vast majority of Holoclar preparations contain suffi-
cient numbers of holoclones for clinical efficacy. This is achieved
Figure 2. Key steps in the manufacture of Holoclar. The figure
shows a simplified flow chart of the manufacture of Holoclar. The
term “drug Substance” is used to denote the cell suspension of epi-
thelial cells obtained after thawing from the frozen primary culture,
and which is ready to be plated on the fibrin matrix, which will yield
the final material for transplant (the “drug product”).
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through use of the mouse feeder cells (cell line 3T3-J2), the combi-
nation of growth factors provided in the culture medium, and
accurate monitoring of culture conditions.
For the authorized product, a standardized training procedure
is made available to surgeons to ensure that the product is applied
in the optimally effective manner, as demonstrated by previous
clinical experience.
SAFETY
An essential purpose of the regulatory agency review is to assure
the safety of medicinal products granted marketing authorization.
It is described below how Holoclar has been able to achieve these
safety standards through design and refinement of the manufac-
turing and testing strategy. The review of clinical experience is
another vital element in the safety assessment of a product, but is
outside of the scope of this article.
Infectious Agents
Critical for the manufacture of any biological product is the safety
from risks of infectious agents that may enter the process from
the source biopsy material, other materials used in the process
(especially those of biological origin) or contamination from the
environment of manufacture. The infectious agent risks that had
to be addressed for Holoclar included the potential for contamina-
tion with bacteria, fungi, viruses, or transmissible spongiform
encephalopathies (TSEs). Certainly there is a risk of microbial con-
tamination associated with the source material taken from a
biopsy of the eye, which is inherently non-sterile as a conse-
quence of the environmental exposure of the ocular surface. Holo-
clar is protected from this danger through extensive dilution by
culture medium and the use of bactericidal (not merely bacterio-
static) antibiotics in the first phase of the manufacture. As it is
undesirable for the product administered to patients to contain
antibiotics, their use is limited to the early stages of the process
(primary culture and cryopreservation of the ICB). The culture per-
formed after cryopreservation (secondary culture) and subse-
quent product preparation steps are performed without
antibiotics. At this stage, without antibiotics, the protection from
new adventitious microbial contamination depends on the good
manufacturing practice (GMP) facilities and rigorous control pro-
cedures required of a commercial manufacturer. Contaminations
that have spread through the culture can be easily visualized, but
Holostem have used sensitive sterility testing to validate that the
manufacture of Holoclar can be maintained free from microbial
contamination after antibiotic removal.
With regard to possible viral contamination of the source
material, the concern is not just for the quality and safety of the
product but also to assure that there is no danger of cross-
contamination of materials from other patients being processed
in the facility. Up to 30 days before biopsy procurement and on
the day of procurement, the patient is serologically screened for a
series of pathogens, namely hepatitis A, B and C viruses, HIV1,
HIV2, human T-lymphotropic virus type I, and West Nile virus. This
allows material from potentially infected patients to be processed
with additional isolation from other patient materials through use
of dedicated production rooms and equipment. As a result, there
is no need to refuse treatment to patients on the basis of a posi-
tive serology test result.
In order to obtain marketing authorization for Holoclar, a com-
prehensive microbial testing strategy also needed to be imple-
mented throughout the manufacturing process. It must be noted
that after preparation the final product must be used within 36
hours, and this does not allow enough time for sterility or myco-
plasma testing. It was therefore recognized by the EMA that the
testing strategy had to depend on in process testing before final
product production. Microbial testing has therefore been imple-
mented at multiple steps in the production:
 Prior to trypsinization of the biopsy in preparation for its pri-
mary culture stage, the biopsy transport media is tested for
mycoplasma and microbial contamination. The species of
bacterial flora of the healthy eye are well known, as they are
described in the control population of typical bacterial infec-
tions of the eye [17, 18]. Therefore, the identification of any
particular species can be assessed to determine whether the
species are considered “normal” or may indicate a particular
eye infection or another source of contamination. The results
are reported back to the treating surgeon for possible treat-
ment of an infection but, as antibiotics are used, the primary
culture processing of the biopsy can continue. In contrast, a
positive mycoplasma test indicates that the cell culture
would be compromised and therefore results in refusal and
no further processing of the biopsy.
 A sample is tested for sterility at the end of the primary cul-
ture stage. At this point, the test can use the 14-day protocol
according to the methodology of the European Pharmaco-
poeia. The cryopreserved hold step provides enough time for
the result to be available before release of the product.
 A sterility test is performed on a sample from the beginning
of secondary culture. At this stage, there is not enough time
for the full 14-day European Pharmacopoeial method, so the
manufacturer uses a more rapid method that was validated
to demonstrate sensitivity that is comparable to that
method. The sample tested represents the latest point in the
process at which the sterility test result can be available for
product release, and also confirms that the process was free
of endogenous microbial contamination at the point where
antibiotics were removed.
 A second pharmacopoeial sterility test is performed on a
sample taken at the final preparation stage of the Holoclar
drug product which is taken just before it is administered. In
this case, the result is not available by the time of product
release, but serves as a confirmation of the absence of prod-
uct contamination.
The other potential sources of infection with infectious agents
are the raw materials. With regard to risks from viral or TSE-
causing agents, the main concerns are materials of animal or
human origin. The manufacturing process for Holoclar uses bovine
serum, porcine trypsin, human fibrinogen, and plasminogen
together with an array of growth factors to promote proliferation
of LSCs. In order to recommend marketing authorization, the CAT
needed to be convinced that all such materials were appropriately
sourced and tested to comply with applicable guidelines and regu-
lations. In some cases, Holostem was required to upgrade
reagents from grades that had been acceptable for clinical use
before marketing authorization, and in other cases additional test-
ing was introduced. Bovine serum was required to be irradiated,
in order to inactivate any potential viral contamination. Another
biological material used in the manufacture that is critical for the
assessment of safety from infectious risk is the layer of feeder cells
that are discussed below.
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Feeder Cells
Ex vivo culture of stem cells frequently requires conditions that
approximate the in vivo microenvironment, or “niche” of a given
stem cell which includes growth factors, cell-cell interactions, and
cell-matrix adhesions that allow the stem cells to remain undiffer-
entiated and retain their characteristics of self-renewal and pluri-
potency [19]. The manufacture of Holoclar uses the mouse
fibroblast 3T3-J2 cell line to form a feeder layer on which the LSCs
can be maintained as such and proliferate. The 3T3-J2 cell line was
established in 1962 [20] and has a well-documented history for its
use as a feeder layer in stem cell culture and for manufacture of
cell products with clinical application in extensive burns. Never-
theless, there are important safety issues to be addressed in the
context of a product to be manufactured for use under a market-
ing authorization.
First, the feeder cells must themselves be assured for absence
of potential to transmit infectious agents to the recipient or to
their cells in Holoclar production cultures. This was achieved by
manufacturing a GMP compliant master cell bank, which was fully
tested for potential viral and other infectious agents according to
established guidelines. By expansion from the master cell bank a
working cell bank was derived, providing a strategy whereby all
future Holoclar manufacture could be conducted with consistent
source cells without a need to ever remanufacture the master cell
bank. Validation studies demonstrated that the performance and
safety characteristics were maintained even when the 3T3-J2 cells
were cultivated to passage levels beyond those used in Holoclar
production.
The second risk to address was that residual lethally irradiated
3T3-J2 cells could persist as impurities in the product. The issue is
then whether these may survive administration to the patient
and, if so, whether there could be any safety consequences. The
level of contamination with mouse cell material is controlled
through release testing. The risk that any live cells could persist in
the recipient is controlled by irradiating the cells (60 Grays, equiv-
alent to 6,000 rads) before use to ensure that they have no long-
term viability. Rendering cells mitotically incompetent by irreversi-
ble lethal irradiation means they cannot survive beyond a few
rounds of passaging [21]. For the CAT, it was a major safety con-
cern that the irradiation must be rigorously validated to ensure
that no mouse cells were left that retained capability for long-
term survival. Holostem was able to demonstrate that irradiated
cells lose proliferative capability, while retaining the capability to
function effectively as a metabolically active feeder layer for the
LSCs (it may be noted that such an irradiation dose is insufficient
to impact significantly on the viral safety considerations noted
above). Furthermore, the company demonstrated that the irradi-
ated 3T3-J2 cells showed no anchorage-independent in vitro
growth potential that could have been characteristic of tumori-
genic cells. Also, analysis from 26 patients that underwent a kera-
toplasty post Holoclar treatment (ranging from 9 months to
almost 8 years after the treatment) found that no 3T3-J2 cells
could be detected in the removed samples of corneal tissue or
basal lamina [11]. Additional supportive evidence of the safety of
irradiated 3T3-J2 cells may be inferred from the history of their
use in other cell-based clinical products, such as the epidermal
cell product Epicel that is authorized in the U.S. for treatment of
skin burns.
LSC autografts that are available without marketing authoriza-
tion in some countries as an alternative to Holoclar frequently do
not use 3T3-J2 cells for the feeder layer. The most widely used cul-
ture method is to grow explant cultures on human amniotic mem-
brane (HAM) as a substratum [22, 23], and consequently the
technique has been used in several products to treat LSCD [9, 10].
Although donors of HAM should be screened for communicable
diseases, the opportunity for testing such primary human tissue is
limited and the assurance of absence of contamination with infec-
tious agents is less than it is for a fully tested cell line. Further-
more, donor-to-donor variability of HAM may affect consistency
of the manufacturing process (see “Quality” section). Similar con-
siderations apply for the alternative approach of using autologous
fibroblasts to form the feeder layer. In controlled comparisons, we
have found that the total clonogenicity and the p63bright LSC con-
tent was markedly greater in keratinocyte populations cultured on
3T3-J2 cells than equivalent cultures grown on feeder layers of
human fibroblasts (see Fig. 3).
Tumorigenicity
Assurance was also needed concerning the behavior and charac-
teristics of the autologous cells in Holoclar. Therefore, the possible
risks of inducing tumorigenesis due to neoplastic transformation
of cells were considered. Keratinocytes from the Holoclar drug
product were cultured in the presence or absence of growth
Figure 3. Comparison of human fibroblast or mouse 3T3-J2 cells
as feeder layers to support human keratinocyte proliferation. Both
types of feeder layer cells were seeded at equal density (700,000
cells per plate) in duplicate after lethal irradiation. Equal numbers of
human keratinocytes (1,000 cells) were then added to each plate.
Following 12 days of keratinocyte culturing, plates were stained and
the colonies counted. Whole plate staining allowed macroscopic
comparison of total keratinocyte proliferation between the two con-
ditions. After 6 days in culture, the parallel mass cultures were
labeled and analyzed in parallel by fluorescent microscopy to deter-
mine the percentage of p63bright cells (holoclones).
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factors, with or without a 3T3-J2 cell feeder layer, to measure the
growth factor dependence with a tumor cell line as positive con-
trol. For cell adhesion analysis the same cells were cultured in a
semi-solid medium (soft agar). In this environment, colony forma-
tion is considered to be indicative of anchorage-independent
growth—a hallmark of tumorigenic and metastatic potential. The
results of all these assays to investigate the possible tumorigenic
potential of Holoclar showed that the Holoclar manufacturing pro-
cess does not transform the patient-derived cells and proliferation
is active only in “physiologic” conditions. Karyotype analysis
revealed a normal phenotype with samples displaying a modal
chromosome numbers of 46, indicating that they all possessed a
normal human diploid karyotype (i.e., no genetic instability). Cells
were entirely dependent on growth factors and the presence of
the 3T3-J2 cell feeder layer, and were unable to form colonies
when grown in soft agar. This in vitro evidence of the absence of
tumorigenic potential is also supported by clinical experience
from over 100 patients with 10 years of follow up showing an
absence of tumorigenicity in vivo [8]. The risk for tumorigenicity is
low because of the absence of genetic transformation. Animal
studies would have been uninformative because of (a) the human
origin of Holoclar, (b) its ocular administration, and (c) the differ-
ences in physiology and anatomy between human and animal
eyes.
QUALITY
Any exploratory (unauthorized) medicine has inherent risks owing
to its limited clinical experience, but quality standards are
required to ensure that the manufacturing process does not intro-
duce additional risks, notably adventitious contamination. Euro-
pean Union Directive 2001/20/EC stipulates that the principles of
GMP should apply to manufacture of investigational medicinal
products for use in clinical trials. GMP compliance is also required
for manufacture of products to be used under hospital exemption
or in compassionate use programmes. This does not mean that
such products are expected to have the same quality standards as
a product that has been granted marketing authorization. In that
case, the manufactured product must also be assured to be con-
sistent with that which was used in the pivotal clinical studies, as
these were the basis for the demonstration of safety and efficacy
on which the marketing authorization was granted.
For a marketed product the whole process must have vali-
dated status conferred by its demonstration of sufficient robust-
ness and capacity to yield a consistent product. A meaningful
process validation is in turn dependent on the quality of the ana-
lytics used to characterize the final product and to monitor the
process, and the understanding of how the results of those tests
relate to the ultimate performance of the product. Put another
way, there needs to be the capability to detect anomalous batches
of product that may not meet the efficacy and/or safety perform-
ance of the authorized product and which accordingly should not
be administered to patients. This is particularly important for an
autologous product such as Holoclar—intrinsic variability of the
starting material has the consequence that final product consis-
tency is not only dependent upon the reproducibility of the proc-
essing steps. The manufacturer therefore needs to understand
and measure the quality attributes that are indicative of efficacy
and safety, and accordingly set quantitative specifications that the
product must meet. Clinicians and patients can then be confident
that the product will be as indicated on the label, and will perform
as described in the associated authorized product information.
In contrast, for a non-commercially authorized product the
manufacturer can only aim to demonstrate consistency with that
used in previous non-clinical studies, such as toxicology work, and
other exploratory clinical experience. This exercise will generally
not be able to define the limits of a safe and effective product and
therefore may fail to detect a product that is aberrant. For prod-
ucts intended for use under hospital exemption, the amended
ATMP regulation (EC/1394/2007) states that manufacturing qual-
ity standards should be “equivalent” to those expected of an
authorized product. However, this should not be understood to
indicate a requirement for process consistency and validation,
which would not be feasible within the qualifying criteria for hos-
pital exemption which include:
“. . ..prepared on a non-routine basis according to specific
quality standards, and used within the same Member State
in a hospital under the exclusive professional responsibility
of a medical practitioner, in order to comply with an indi-
vidual medical prescription for a custom-made product for
an individual patient.”
(EC/1394/2007 Article 28, 2).
To achieve marketing authorization, the manufacturer must
demonstrate validation of the entire manufacturing process and
associated analytical methods. This higher level of quality assur-
ance is recognized in the GMP certifications granted to manufac-
turing organizations that normally specify whether the facility is
authorized to manufacture medicinal products for commercial
use, or other uses, such as clinical trials. For either type of certifi-
cation, within the EU the GMP facility inspections will generally be
conducted by the responsible national agency. National agencies
are also normally responsible for authorizing an application to per-
form a clinical trial. However, it should be noted that the manufac-
turing information that is reviewed, from the content of the
Investigational Medicinal Product Dossier, is normally much less
than that given in the detailed dossier (known as the Common
Technical Document) that must be reviewed by the EMA for an
application for marketing authorization.
Extensive experience from batches manufactured for clinical
application was used to set the product release specifications.
Holostem was also able to undertake specifically designed valida-
tion studies using samples taken from donated cadaveric corneas
(due to the long-term post-mortem epithelial viability) that were
shown to be representative of biopsies from living donors. The
feasibility and validity of the latter approach was important, as the
biopsy material from living patient donors had to be exclusively
reserved for use in treatment of those patients. It would also have
been unethical to biopsy healthy donors for this purpose. The first
round of validation studies using cadaveric corneas showed the
consistency of production, including multiple batches prepared
from the same source material which demonstrated manufactur-
ing consistency independent of donor-to-donor variability. A par-
ticularly high degree of consistency was found between replicate
secondary cultures derived from the same primary culture
(Table 2).
A second round of validation studies demonstrated that the
key quality attributes of the product were maintained when pro-
cess refinements were introduced (such as the use of the 3T3-J2
working cell bank, and the elimination of antibiotics from the
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second stage of cell culturing), and also encompassed stability
studies for the final product and key process intermediates. Stabil-
ity of the frozen ICB is significant as the amount of intermediate
generated can be sufficient to enable more than one Holoclar
graft to be produced from a single biopsy starting material. The
opportunity to manufacture a second graft from a stored ICB can
provide the patient with additional options in case of failure of
the first graft or clinical need for a further graft. The recognition of
a clinical need for a second engraftment is likely to be considered
6–12 months after the first Holoclar graft. Therefore a correspond-
ing shelf life for the ICB would be of significant benefit for the
patient to avoid the need for a new biopsy to generate more start-
ing material. Based on the data shown in Table 3, a shelf life of
366 days for the ICB was accepted at the time of marketing
authorization approval.
As part of the study, data to support the assigned shelf life of
36 hours of drug product (between manufacture and use) were
obtained from 31 lots of Holoclar manufactured from six cadaveric
corneas and held for 40 hours, including vibration to simulate
transport conditions and excursion temperature times. Material
from these studies was also used to establish that the product
maintains its properties when used, according to its instructions,
within 15 minutes of opening of its primary container under ambi-
ent conditions.
Together, manufacturing process validation and sound product
characterization (with validated analytical techniques) have given
Holoclar the assurance that it can be produced and used under
real life conditions with retention of its critical quality attributes.
CONCLUSION
The decision made by Chiesi together with Holostem and Academia
to seek marketing authorization for Holoclar was not taken lightly as
significant investments from all partners were required in order to
bring the product production up to the required standard and to
assemble the clinical and non-clinical data for the filing. Resources
were also required to progress through the regulatory procedure,
including preparatory steps such as building and certifying a new
facility, regulatory scientific advice procedures, application for
orphan drug status, approval of a paediatric investigation plan, an
ATMP classification procedure, and finally the marketing authoriza-
tion application itself. This article has described the manufacturing
upgrades that were undertaken for the application, and the benefits
that these have brought to the patients that receive the product.
A critical element of manufacturing for an authorized product
is validation. This ensures that a product manufactured under that
authorization is consistent with that for which the positive
benefit-risk ratio (between efficacy and safety) has been estab-
lished from clinical experience. For Holoclar, the scientific under-
standing that efficacy depends on the presence of LSCs
(holoclones), and the knowledge that the content of these cells
can be determined from immunostaining for the p63 marker,
Table 3. Percentage of p63bright and other cell populations during storage of the intermediate cell bank
Batch Marker Time point 1 Time point 2 Time point 3 Time point 4 Time point 5
0116561 Time 14 days 31 days 164 days 184 days 366 days
p63bright (%) 3.9 3.3 3.2 3.0 2.5
K31 (%) 70 76 64 57 53
Viability (%) 71 65 64 61 65
0117082 Time 12 days 33 days 160 days 187 days 368 days
p63bright (%) 3.6 4.3 4.2 3.1 2.7
K31 (%) 69 65 70 67 67
Viability (%) 72 81 70 81 81
0117243 Time 9 days 30 days 156 days 176 days 366 days
p63bright (%) 4.3 3.2 3.9 3.5 3.0
K31 (%) 71 71 64 77 73
Viability (%) 84 84 75 80 71
Table 2. Validation study showing consistency between cultures from the same or different primary culture
Primary culture Secondary culture
Test
p63bright (%) K31 (%) CFE (%) Viable cells (%) Cell yield
1 a 8.6 90.3 14.2 74.6 315,000
b 8.4 83.1 22.5 80.0 225,000
2 a 8.2 70.1 14.3 66.5 375,000
b 7.2 72.1 25.9 66.7 415,000
3 a 6.3 67.8 13.5 82.5 250,000
b 5.5 81.3 18.0 61.6 300,000
Mean 7.4 77.5 18.1 72.0 313,333
SD 1.3 8.8 5.1 8.3 72,296
Abbreviation: CFE, colony forming efficiency (measures the number of epithelial colonies that originate following culture).
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resulted in the correlation of this measurable product characteris-
tic with positive clinical outcome. As a consequence, the manufac-
turing process has been optimized to maintain sufficient content
of these cells, thus minimizing the chance of patients being admin-
istered a product with low efficacy. A number of measures were
implemented that improved the safety of the product. Notably
these included a comprehensive strategy toward elimination of
microbial contamination that is inherently possible in the source
tissue. This strategy had to be sufficiently robust to allow
antibiotic-free culture of cells in the later stages of the process,
and was achieved by incorporating controls to minimize risks of
any subsequent contamination. Another potential safety risk arose
from the xenogeneic feeder cell layer needed for the cultivation of
LSCs. While a number of groups use classic laboratory techniques
utilizing primary human tissue, such as amniotic membrane as a
support matrix (with or without heterologous donor cells pres-
ent), such a source is less than ideal for the consistency and high
safety standards expected of an authorized medicinal product. The
3T3-J2 mouse cell line used for the feeder layer in Holoclar pro-
duction is derived from established master and working cell banks
providing (a) consistency of material, (b) security of supply, and (c)
safety through thorough extensive testing for virological risks. In
addition the cells are irradiated using a protocol that has been
validated to demonstrate absence of residual cells with any ability
to continue replication in a recipient. Studies have also been car-
ried out to show that neither the autologous nor the feeder cells
exhibit tumorigenic characteristics (Table 4).
The efficacy and safety factors described above can also be
seen as part of the overall quality package that is needed to
achieve marketing authorization. The extensive characterization
and demonstration of consistency (albeit within the context of the
high intrinsic donor-to-donor variability) provided a basis on which
the manufacturing process could be refined with confidence that
the safety and efficacy of the product will not be compromised.
Another important feature is validation of the storage times,
transportation and in-use procedures to provide assurance that
the product retains its required properties from manufacture right
up to the moment of administration to a patient.
The product upgrades required to achieve marketing authori-
zation do require significant expenditure. As well as the costs for
clinical studies, upgrading the product quality to meet EMA
requirements will typically require investment in the manufactur-
ing, including in facilities and their maintenance, additional analyt-
ical tests, raw material controls, and validation of the
manufacturing process and analytical assays. Other costs will
include those for regulatory filings, post-approval variations, pro-
cess revalidation, and pharmacovigilance.
While the theme of this paper has been the improvements
made in Holoclar in order to obtain EU marketing authorization,
the context in which non-commercially authorized therapies may
be used should not be forgotten. Clinical trials are essential for
the development of new therapies, and provide the dosing, safety
and efficacy data upon which a future marketing authorization
can be based. At the clinical trial stage there are evidently risks
inherent in the use of an experimental medicine that has had lim-
ited controlled assessment in humans, and developers must
design their studies to minimize these risks. The manufacturer
may not know precisely which product attributes are critical for
clinical performance but should manufacture the product to GMP
standards to avoid the introduction of additional risks. Treatments
performed under compassionate use schemes and, even more so,
hospital exemption provisions for ATMPs, also involve use without
Table 4. Distinctive characteristics of Holoclar manufacturing and their implications for clinical use
Manufacturing process Rationale/implications for clinical use
Raw materials Use of compendial materials/highest possible standards Minimization of contamination potential
Irradiation of bovine serum Inactivation of potential viral contamination
Consistency of production Analysis of multiple batches from the same source material Consistency of expected product characteristics
Source material (Biopsy)  Bactericidal antibiotics used in the primary culture
 GMP facilities with rigorous control procedures
 Sensitive microbiological testing
Minimization of contamination potential
Serological examination of the patient and additional isolation
of infected material
Possibility of treating also seropositive patients
Feeder layer Greater clonogenicity and LSC content of keratinocytes cultured
on 3T3-J2 mouse cells than on human fibroblasts
Maximization of clinical performance
of the product
GMP compliant master cell bank fully tested for viral and
other infectious agents
Minimization of contamination potential
Validated irreversible lethal irradiation protocol Absence of 3T3-J2 cells in the
recipient cornea
Frozen intermediate
cell bank
Validation of 366 days of shelf-life Potential opportunity to manufacture a
second graft without the need of
a new biopsy
Analysis of cultured
autologous cells
 Karyotype
 Growth factor and feeder layer dependence
 Soft-agar assay
 Long-term replicative senescence, absence of immortalization
Absence of tumorigenic potential
LSC content Holoclar is released only if p63bright cells in the Drug Substance
are in 2.54 16% range
Association to higher clinical success rate
Drug product stability Validation of 36 hours of total shelf-life and 15 minutes from
opening of primary container
Possibility to use under real life conditions
Abbreviations: GMP, good manufacturing practice; LSC, limbal stem cell.
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the support of approved clinical, non-clinical and manufacturing
data sets that can enable authorization. In the case of compas-
sionate use, this may only be a temporary arrangement while an
application for marketing authorization is ongoing. However, hos-
pital exemption is designed for customized patient-specific prod-
ucts for which a marketing authorization may never be feasible. In
some such cases a therapy that is patient-specific, and therefore
apparently so non-routine as to be unsuitable for the marketing
authorization route, may subsequently find itself alongside a simi-
lar therapy that has actually achieved authorization. This may well
have been the case with LSC products, like Holoclar, which some
may have thought, as a complex autologous therapies, would not
be amenable to marketing authorization. However, Chiesi and Hol-
ostem are pleased to have been able to demonstrate that this was
possible for Holoclar, and the manufacture of such a therapy could
be developed to the validated quality required. As a result,
patients can have access to a therapy that is manufactured to
high commercial standards and consistency. Holoclar is supported
by clinical safety and efficacy data that have been subjected to
intense regulatory review and by continuing obligations according
to the risk management plan and other conditions of approval.
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